Aslan Pharmaceuticals Pte. Ltd., of Singapore, licensed a preclinical immuno-oncology antibody, targeting RON (Recepteur d'Origine Nantais), from Singapore's Agency for Science, Technology and Research (A*STAR) with plans to develop and commercialize it globally.